WHO ICTRP trial
A Prospective Clinical Study of Low-Dose Daratumumab Therapy for Refractory…
ChiCTR2400091558 · Chinese Clinical Trial Registry (ChiCTR) · Not Recruiting
Key facts
| Trial ID | ChiCTR2400091558 |
|---|---|
| Public title | A Prospective Clinical Study of Low-Dose Daratumumab Therapy for Refractory Primary Immune Thrombocytopenia |
| Scientific title | A Prospective Clinical Study of Low-Dose Daratumumab Therapy for Refractory Primary Immune Thrombocytopenia |
| Primary sponsor | the First Affiliated Hospital of University of Science and Technology of China |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Not Recruiting |
| Study type | Interventional study |
| Phase | 0 |
| Countries | China |
| Conditions | Primary Immune Thrombocytopenia |
| Interventions | Experimental group:A low dose of daratumumab 8mg/kg was given intravenously weekly for 8 weeks (a total of 8 doses). |
| Registration date | Oct 30, 2024 |
| Target size | Experimental group:20 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: